GSK Investigator-sponsored studies programme





GSK Investigator Sponsored Studies

Our mission

At GSK, we are dedicated to improving the quality of human life by enabling people to do more, feel better and live longer. As part of this commitment, we recognise the valuable role that our support of Investigator-sponsored studies (ISS) plays in fulfilling this mission.

An investigator sponsored study is research conducted by an external Sponsor, with GSK's support. The Sponsor of the study is an external investigator, healthcare institution, or medical network and is seeking support from GSK to conduct the study which can be in the form of funding, drug product (including GSK products, adjuvant for vaccines, placebo, or other medicinal products necessary for the research), or both.

The decision to support a study is based on:

  • The importance and innovation of the research objectives to medical science or patient care
  • Alignment with GSK's current areas of interest, and
  • The ability of the study Sponsor to deliver a high-quality ethical study
  • Assessment of the resource request matched against what GSK has available

We do not support ISS in order to reward healthcare professionals for using, purchasing, recommending, or prescribing GSK products or to persuade them to do so. GSK is not committed to provide support (product or funding) until a legal agreement has been signed by both parties.

Areas of Interest

Please find below the current area of interest per therapy area. These may be updated ahead of each submission area:

  • Vaccines

  • Pharma

  • Consumer Healthcare

Submission timelines

GSK is committed to responding to your Proposal within 8 weeks from the closing date. Please find below the next submission and review dates for submitted proposals within each Therapy Area.

This is a step change for GSK. Following feedback from our external partners on the ISS process, we are refining our ISS submission process, to enable us to review and respond to proposals in an accelerated and more effective manner; and select proposals that best advance science and patient care. We welcome your ongoing feedback.

Therapeutic Area Proposal submission period opens Proposal submission period close Proposal of Interest communication date Further Information
Vaccines Opens on 1 December 2018 28 February 2019 25 April 2019 These submission timelines are for Human Subject Research ISS. Please continue to submit your non-Human Subject Research ISS (e.g. preclinical) at any time. They will be reviewed on reception
Pharma - Immunology, Inflammation and Future Pipeline (belimumab) (Cycle 2) 01 February 2019 15 July 2019 30 September 2019
Pharma - Immunology, Inflammation and Future Pipeline (belimumab) (Cycle 1) Closed for submission 31 January 2019 31 March 2019
Pharma - Respiratory 17 May 2019 26 July 2019 20 September 2019
Pharma - Classic and EstablishPharma - Classic and Established Products (Marketed Products) 30 January 2019 10 April 2019 05 June 2019
Pharma - Oncology >01 April 2019 07 June 2019 02 August 2019
Consumer Healthcare Opens 7 January 2019 29 March 2019 10 May 2019

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology that supports human subject research.

Sponsors can request access to anonymised patient-level data from GSK sponsored clinical studies via the following link: https://clinicalstudydatarequest.com/

Note:Brexit- For attention of sponsors with an active study in UK_EU_29th March 19

Notification on belimumab proposals:

New Investigator Sponsored Study Proposals within our current areas of interest may be submitted up to 15th July 2019. To know more about this or to submit your Proposal please click on the following link

Submit Application


Terms of use Accessibility Cookie policy Privacy
© 2001-2019 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.